-
Rich pipelines and reasonable gradients... Domestic innovative giant pharmaceutical companies are concerned
Time of Update: 2021-12-08
Among them, the research and development expenses of Hengrui Pharmaceuticals in the first three quarters increased by nearly 24% year-on-year, reaching 4.
For example, 33 pharmaceutical companies, such as Guofa, Dashenlin, and Guangzheng Ophthalmology, experienced a year-on-year growth rate of over 100% in R&D expenses in the first three quarters .
-
Shenzhen's strategy for monitoring and management of drug prices: 4491 pharmacies’ medical insurance drug prices are “in your hands” at any time
Time of Update: 2021-12-08
On November 10, the Shenzhen Municipal Medical Insurance Bureau launched the "Medicare Drug Price Link" medical insurance drug price inquiry service, covering 4,491 designated retail pharmacies in the city .
-
What direction does the 2021 policy of the pharmaceutical equipment industry indicate for the development of the industry?
Time of Update: 2021-12-08
Judging from these two documents, green, low-carbon, high-end equipment with a high level of automation will be the next direction for the API equipment industry to continue its efforts and research .
-
Market forecast: The domestic antibiotic industry as a whole may maintain greater demand in the next few years
Time of Update: 2021-12-08
Data show that in recent years, under the implementation of antimicrobial control measures such as the graded management of antibiotics, the scale of China's antibiotics market has grown slowly .
-
Since November, a number of domestically produced Class 1 new drugs have been applied for clinical application and marketing
Time of Update: 2021-12-08
Prior to this, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng has also received CDE approval for the marketing application of Brainshang Lesheng Granules submitted by the new drug category 1.
-
Domestic orphan drug giant joins hands with Pfizer to jointly develop breast cancer treatment
Time of Update: 2021-12-08
Specifically, the two parties will jointly develop Lisaftoclax (APG-2575), a selective Bcl-2 inhibitor of Ascent Pharmaceuticals, combined with Pfizer's CDK4/6 inhibitor, Aiboxin (pibacillil), for the treatment of relapsed and locally advanced stages.
-
Domestic new drug research and development has entered a period of rapid development, and pharmaceutical companies have set off a "financing fever"
Time of Update: 2021-12-08
Recently, Zhimeng Pharmaceutical, a chronic liver disease treatment drug developer, announced that it has completed 350 million yuan in round B financing.
-
What you have to know about medicinal excipients with more than 100 billion growth space for lips and teeth
Time of Update: 2021-12-08
US FDA:Pharmaceutical excipients are inactive ingredients in preparations other than the main drug (API)"Japanese Pharmacopoeia":In addition to the specially specified substances, in order to ensure the properties and quality of the preparations and improve the compliance of the preparations during the storage process, excipients, stabilizers, preservatives, buffers, correctives, and auxiliary agents may be added as needed.
-
Domestic pharmaceutical companies are accumulating in the field of anti-tumor drugs, and good news comes out frequently
Time of Update: 2021-12-08
For example, on November 8, Hengrui Medicine issued an announcement stating that two anti-tumor drugs with a research and development investment of over 640 million yuan were approved for clinical trials .
-
The "authorized introduction" innovative drug model is hot, and the product lines of local pharmaceutical companies are becoming more and more abundant
Time of Update: 2021-12-08
(KoBioLabs) have reached a licensing cooperation to obtain the development of new probiotic drugs KBL697 and KBL693 projects in China (including Hong Kong, Macau and Taiwan) , Production, registration, distribution, sales, marketing, promotion and relicensing rights, including all indications of KBL697 and KBL693 as medicines, as well as the exclusive rights of KBL697 and KBL693 as food, health products, and special medical foods .
-
With the continuous expansion of the Chinese medicine formula granule test market, two major issues cannot be ignored
Time of Update: 2021-12-08
On November 1, the State Food and Drug Administration and other departments ended the more than 20-year pilot work of traditional Chinese medicine formula granules, and officially launched the registration module of traditional Chinese medicine formula granules .
-
In order to ensure the safety of drugs, detailed regulations on drug supervision are issued in many places
Time of Update: 2021-12-08
Since May 28, the relevant state departments have announced the "Administrative Measures for Drug Inspection (Trial)" (hereinafter referred to as the "Measures"), which clearly requires that in order
-
AstraZeneca's IL-5 inhibitor Fasenra was granted fast track approval by the FDA
Time of Update: 2021-12-08
S. Food and Drug Administration as a fast-track approval designation for the treatment of eosinophilic gastroenteritis with or without it.
-
The pharmacy's strictest inspection is here
Time of Update: 2021-12-08
The "Detailed Rules" clearly requires that the provincial drug regulatory bureau (hereinafter referred to as the provincial bureau) conduct related inspections for drug retail chain headquarters, third-party drug online trading platforms, drug wholesale companies, drug manufacturers and other units, and the provincial bureaus shall check the drug safety risks Take effective risk control measures to organize the investigation and punishment of the above-mentioned corporate violations of laws and regulations and major cross-regional violations of laws and regulations .
-
Drug Administration issued a document to regulate online prescription drugs
Time of Update: 2021-12-08
The "Regulations" stated that when pharmaceutical retail companies sell prescription drugs online, they should ensure that the source of electronic prescriptions is authentic and reliable, conduct prescription deployment reviews in strict accordance with relevant requirements, and mark the use of electronic prescriptions that have been used .
-
GlaxoSmithKline first-in-class antibiotics apply for clinical application in China
Time of Update: 2021-12-08
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn November 11, the CDE official website showed that the clinical application of GSK's new antibiotic Gepotidacin tablets was accepted by the State Food and Drug Administration .
-
A pharmacy lost 500,000 yuan due to illegal sales of prescription drugs
Time of Update: 2021-12-08
However, during the epidemic prevention period, pharmacies who sell prescription drugs in violation of regulations are often severely punished .
In response, the two pharmacies had their business licenses revoked for failing to sell drugs to confirmed cases in accordance with regulations .
-
In order to accelerate innovation, pharmaceutical companies set off a "wave of cooperation"
Time of Update: 2021-12-08
For example, on November 10, Tianjing Bio announced that it had reached a product development, production and commercialization cooperation with Jichuan Pharmaceutical on the highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (eftansomatropin alfa, TJ101) .
-
Fierce Biotech's 2021 biopharmaceutical Waterloo event inventory
Time of Update: 2021-12-08
Last year the company’s hype about the 3-phase leronlimab trial missed its primary and all major secondary endpoints, but the company borrowed from COVID-19 gimmicks, and its stock price continued to rise in the process .
-
The 2021 edition of the basic medicine catalog management method is released!
Time of Update: 2021-12-07
The types and quantities of adjustments should be determined based on the following factors: (1) China's basic medical and health service needs and basic medical security level changes; (2) China's disease spectrum changes; (3) Adverse drug reaction monitoring and evaluation; (4) Drug use monitoring And clinical comprehensive evaluation; (5) Evidence-based medicine and pharmacoeconomic evaluation of marketed drugs; (6) Other conditions specified by the National Essential Medicines Working Committee .
